Endocrine oncology

Overlapping Presentations and Diverse Genetic Defects Characterize Neuroendocrine Neoplasms in a Mexican Cohort

J Clin Endocrinol MetabPublished Cross-sectional genetic study

Authors' conclusion

P/LP variants were identified in 17.4% of individuals with NENs. Our research provides a view of the landscape of NEN drivers in a population not previously characterized.

Study context

Population
Mexican adults with neuroendocrine neoplasms (NENs) (syndromic and nonsyndromic); 70.7% women, 51.5% sporadic
Participants
92 probands
Exposure
P/LP variants vs Rest
  • P/LP variantsn = 16
Outcome
Frequency, inventory and clinical associations of germline defects associated with NENs
Methodological details53-gene next-generation sequencing panel, Sanger sequencing, orthogonal confirmation
  • 53-gene next-generation sequencing panel
  • Sanger sequencing
  • Orthogonal confirmation

Main finding

As reported in the abstract

P/LP germline variants
Probands carrying P/LP variants
16
P/LP variants in individuals with NENs
17.4%
Likely driving variants in Von Hippel Lindau syndrome cases
three-quarters
Likely driving variants in MEN1
one-third
Likely driving variants in early-onset acromegaly/gigantism
one-quarter
Clinical MEN1 with an SDHA variant
1

Observational data: associations, not effects.

Further findings

OutcomeRestP value
Age at disease onsetP/LP carriers vs Rest · significantly younger with P/LP carriers40 (range 21.5–51.5) yearsP = 0.0384
P/LP variants, familial vs sporadicMore likely with familial diseaseP = 0.0282
  • Age at disease onset: P/LP carriers 29.6 ± 10.7 years
  • P/LP variants, familial vs sporadic: Familial 26.7 %
  • P/LP variants, familial vs sporadic: Sporadic 8.5%

Original publication

Overlapping Presentations and Diverse Genetic Defects Characterize Neuroendocrine Neoplasms in a Mexican Cohort. J Clin Endocrinol Metab. Published 5 February 2025. doi:10.1210/clinem/dgaf075

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.